Table 1.
Demographic and clinical characteristics of all enrolled populations
| Discovery cohort | p-value | Validation cohort | p-value | |||||
|---|---|---|---|---|---|---|---|---|
| HC (n=35) | HCC (n=55) | HC (n=45) | CHB (n=125) | LC (n=38) | HCC (n=63) | |||
| Age (years) | 41.14±9.24 | 51.09±13.65 | <0.001 | 45.41±12.95 | 35.41±10.55 | 44.92±11.30 | 51.48±13.07 | <0.001 |
| Gender (male, %) | 15, 42.86% | 47, 85.45% | <0.001 | 23, 51.11% | 111, 88.8% | 32, 84.21% | 52, 82.54% | 0.14 |
| ALT (U/L) | 20.34±12.40 | 49.56±32.01 | <0.001 | 20.45±14.17 | 77.32±84.23 | 84.81±95.83 | 48.19±30.84 | <0.001 |
| AST (U/L) | 19.74±8.00 | 67.36±52.09 | <0.001 | 19.38±6.09 | 45.76±37.38 | 62.62±51.60 | 64.28±49.51 | <0.001 |
| TBil (μmol/L) | 14.26±4.28 | 25.66±23.37 | 0.001 | 13.95±4.53 | 15.85±20.23 | 25.88±22.18 | 25.29±21.14 | <0.001 |
| DBI (μmol/L) | 2.83±0.96 | 8.35±12.79 | 0.002 | 2.77±0.96 | 4.78±3.05 | 10.25±14.32 | 8.06±12.0 | <0.001 |
| ALB (g/L) | 43.60±2.62 | 36.14±6.53 | <0.001 | 44.09±2.65 | 45.10±5.13 | 39.92±7.08 | 36.22±6.55 | <0.001 |
| PLT(/L) | 239.17±50.96 | 182.6±134.45 | 0.006 | 238.1±51.80 | 191.5±54.27 | 127.6±62.26 | 173.8±129.0 | <0.001 |
| HBV DNA (log10 IU/ml) | 1.91±1.30 | 6.81±1.99 | 4.33±3.03 | 1.70±2.10 | <0.001 | |||
| HBeAg (positive, %) | 8, 14.55% | 96, 76.8% | 13, 34.21% | 10, 15.87% | 0.91 | |||
| AFP (<13.4 ng/ml, %) | 26, 47.27% | 30, 47.62% | ||||||
Abbreviations: HC, healthy control; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; LC, liver cirrhosis; ALT, alanine transaminase, AST, aspartate transaminase; TBil, total bilirubin; DBI, direct bilirubin; ALB, albumin; PLT, platelet; HBeAg, hepatitis B e antigen; AFP, alpha-fetoprotein.